Regeneron Grants Long-Term PSUs to CEO, CSO

The PSU grants signal an explicit management emphasis on long-term value creation. Tying equity awards to a 10-year growth horizon is consistent with a strategy that prioritizes multi-year execution on late-stage clinical programs, manufacturing scale-up and collaboration monetization. The company’s stated strategy for the next three years centers on advancing its proprietary platforms, prioritizing Phase 3 readouts in ophthalmology and oncology, and expanding collaboration-derived revenue. From an operational and financial perspective, Regeneron’s 2025 net product sales were heavily concentrated in the EYLEA family, which accounted for $7,891.0 million of net product sales (55% of total net product sales). Geographically, the EYLEA family was 56% U.S. and 44% Rest of World in 2025, down from a U.S. share of 63% in 2024 and 2023. Collaboration and profit-share arrangements (for example with Sanofi) supplement the company’s product sales and are a core element of management’s revenue diversification plan. The company’s competitive position is supported by proprietary discovery platforms such as VelocImmune® and the broader VelociSuite®, which underpin key assets and the pipeline. The provided assessment characterizes Regeneron’s economic moat as narrow: patent-protected advantages and integrated manufacturing provide value but the business remains exposed to biosimilar erosion, patent litigation and competitive ophthalmology entrants. These structural risks are directly relevant to long-term incentive design, since sustained outperformance depends on successful patent defense, pipeline execution and commercial resilience. Key risk factors from the company’s FY2025 disclosures remain material to how those PSUs could ultimately vest: ongoing patent litigation (including EYLEA-related biosimilar challenges), regulatory milestones and potential collaborator or market concentration issues. The company’s MD&A and business strategy emphasize mitigating EYLEA concentration by advancing other products (Libtayo, Praluent, and smaller contributors) and growing collaboration revenue, which are logical performance levers for a 10-year award structure.

Long-duration PSUs generally aim to align executive incentives with durable enterprise value rather than short-term quarterly metrics. For Regeneron, the structural drivers that would support long-term PSU attainment are: (1) maintaining EYLEA’s market position and managing biosimilar risk, (2) delivering Phase 3 and commercial milestones in ophthalmology and oncology, (3) expanding profitable collaborations that provide recurring profit-share revenue, and (4) protecting and leveraging VelocImmune® and related platform IP. Conversely, the primary operational and legal headwinds cited in the company’s filings—patent litigation, regulatory uncertainties, and customer concentration—are material upside/downside factors for long-term outcomes. Investors evaluating the PSU grant should weigh whether the 10-year targets reflect achievable growth given these documented risks and the company’s stated diversification strategy.